Compare McKesson Corporation (MCK) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs STMicroelectronics NV — how do they compare? McKesson Corporation trades at $829.3 (market cap $97.35B), while STMicroelectronics NV trades at $64.72 (market cap $55.80B). The key difference: McKesson Corporation is the larger of the two by market cap, and STMicroelectronics NV pays the higher dividend (0.58%). Which is the better fit depends on your goals.
| MCK | STM | |
|---|---|---|
Market Cap | $97.35B | $55.80B |
Sector | Health | Financials |
52-Week High | $995.69 | $79.91 |
52-Week Low | $659.01 | $21.20 |
Enterprise Value | $101.98B | $54.01B |
Dividend Yield | 0.39% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
STM trades at $61.57, down 0.79% with a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 387.88 but strong analyst support (51.72% buy rating). Recent earnings have been inconsistent with two misses in the last three quarters, though Q3 2025 beat expectations. The company maintains solid cash flow generation of $555M in 2025 and is expanding AI partnerships with AWS and NVIDIA to drive future growth.
STM presents a cautious opportunity with 15% upside to the $72.33 consensus target, supported by AI expansion but tempered by declining revenue and thin 1.19% net margins. Key risks include execution on AI initiatives and semiconductor market volatility. The current price near support at $60 offers potential entry but requires monitoring of Q2 earnings due soon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
